Roche Partners with Chinese Biotech for Molecular Glue Medicines

Roche has entered into a drug discovery collaboration with Chinese biotech Defand Therapeutics, focusing on molecular glue medicines for cancer and immune-driven diseases, marking a potential shift in global drug development.

Why it matters. This partnership could accelerate the development of innovative cancer treatments and strengthen Roche's presence in the Chinese biotech market.